University of Alberta
π¨π¦Canada
- Country
- π¨π¦Canada
- Ownership
- Private
- Established
- 1908-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.ualberta.ca
Milk-derived Gangliosides for Inflammatory Bowel Disease
Phase 1
Withdrawn
- Conditions
- Inflammatory Bowel Disease
- Interventions
- Dietary Supplement: PlaceboDietary Supplement: Ganglioside
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- University of Alberta
- Registration Number
- NCT02139709
- Locations
- π¨π¦
Zeidler Ledcor gastroenterology clinic, Edmonton, Alberta, Canada
Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)
Phase 4
Completed
- Conditions
- Acute Pancreatitis
- Interventions
- Drug: Rectal indomethacin 100mg one time before or after ERCP
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2017-10-25
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 534
- Registration Number
- NCT02111707
- Locations
- π¨π¦
University of Alberta, Edmonton, Alberta, Canada
Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke
Phase 2
Completed
- Conditions
- Cerebral InfarctionBrain IschemiaStroke
- Interventions
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 20
- Registration Number
- NCT02101606
- Locations
- π¨π¦
University of Alberta, Edmonton, Alberta, Canada
Solar Powered Oxygen Delivery
Phase 2
Completed
- Conditions
- HypoxemiaPneumonia
- Interventions
- Device: Solar powered oxygenDevice: Oxygen from cylinders
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 130
- Registration Number
- NCT02100865
- Locations
- πΊπ¬
Jinja Regional Referral Hospital, Jinja, Uganda
Outcomes of Angiotensin Converting Enzyme Inhibitor Management Strategies Prior to Coronary Artery Bypass
Phase 2
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- Drug: ACE/ARB withdrawalDrug: ACE/ARB continuation
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2018-03-22
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 126
- Registration Number
- NCT02096406
- Locations
- π¨π¦
University of Alberta Hospital, Edmonton, Alberta, Canada
Personalized "Alberta" Diet for Prevention of Relapse in Ulcerative Colitis
Not Applicable
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Behavioral: Alberta Anti-inflammatory dietBehavioral: Canada's Food Guide Diet
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2018-05-02
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 53
- Registration Number
- NCT02093780
- Locations
- π¨π¦
University of Alberta, Edmonton, Alberta, Canada
Oligofructose-enriched Inulin for the Treatment of Mild to Moderate Active Ulcerative Colitis
Not Applicable
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Dietary Supplement: Synergy1
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 24
- Registration Number
- NCT02093767
- Locations
- π¨π¦
University of Alberta, Edmonton, Alberta, Canada
Assessment of Arachidonic Acid Supplementation in Infant Formula on the Immune Response of Infants
Phase 1
Completed
- Conditions
- Focus: Nutritional Requirements for Infants
- Interventions
- Dietary Supplement: PlaceboDietary Supplement: Arachidonic acid (34 mg/100 kcal)Dietary Supplement: Arachidonic acid (25 mg/100 kcal )
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2014-04-25
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 89
- Registration Number
- NCT02092857
- Locations
- π¨π¦
University of Alberta Hospital, Edmonton, Alberta, Canada
Chest Compression and Sustained Inflation
Not Applicable
Completed
- Conditions
- Newborn Infants Having Asystole or Bradycardia at Birth
- Interventions
- Procedure: CC+SI
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 9
- Registration Number
- NCT02083705
- Locations
- π¨π¦
Royal Alexandra Hospital, Edmonton, Alberta, Canada
An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia
Phase 1
Completed
- Conditions
- Choroideremia
- Interventions
- Genetic: rAAV2.REP1 vector
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 6
- Registration Number
- NCT02077361
- Locations
- π¨π¦
University of Alberta, Edmonton, Alberta, Canada
Β© Copyright 2025. All Rights Reserved by MedPath